Construction starts for Sartorius' new Cell Culture Technology Centre
The 30-million-euro investment will accommodate the growing needs of customers.
Sartorius Stedim Cellca is building a new 30-million-euro Cell Culture Technology Center at Science Park III in Eselsberg situated at the northwestern scientific hub of the city of Ulm, Germany. Hugo de Wit, Managing Director, and Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG, symbolically broke ground in the presence of around 100 guests, marking the official start of construction work. “This is a significant step for Sartorius Stedim Cellca and our staff to soon be able to work in an advanced new complex. We are very proud of this as the new, modern facility will enable us to continue accommodating the growing needs of our customers in the future as well,” said de Wit.
So far, Sartorius Stedim Cellca has been working in a rented building in Laupheim. The new laboratory and office complex will approximately double the company’s space and is scheduled to be completed by the end of 2019. In addition, relocation to this zone will provide closer proximity to universities and research institutes that are based in Ulm’s Science Park. In addition, this move to the new facility, which is conveniently accessible by various transportation routes between the large cities of Stuttgart and Munich, will make it even easier for international customers to visit the company. Sartorius Stedim Cellca purchased the property of more than 6,000 m2 at Science Park III back in November 2016 and can, therefore, expand its Cell Culture Technology Center by a further 5,000 m2 as needed.
Sartorius Stedim Cellca develops cell lines and protein production processes, licenses technologies for the production of proteins and offers cell culture media. The company has been a part of the biopharma equipment supplier Sartorius Stedim Biotech since 2015 and currently employs around 90 people. Over the medium term, the company plans to extend its workforce to more than 120 people.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance